Syncom Formulations (India) Ltd
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]
- Market Cap ₹ 1,888 Cr.
- Current Price ₹ 20.1
- High / Low ₹ 27.9 / 11.0
- Stock P/E 56.9
- Book Value ₹ 3.34
- Dividend Yield 0.00 %
- ROCE 10.8 %
- ROE 9.10 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Stock is trading at 6.05 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.14.1 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE Allcap BSE SmallCap BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|
115 | 151 | 173 | 184 | 185 | 216 | 222 | 262 | 328 | |
104 | 135 | 155 | 167 | 168 | 196 | 202 | 232 | 290 | |
Operating Profit | 11 | 16 | 18 | 17 | 17 | 20 | 20 | 30 | 38 |
OPM % | 9% | 11% | 11% | 9% | 9% | 9% | 9% | 11% | 12% |
1 | 1 | 1 | 3 | 3 | 12 | 15 | 14 | 14 | |
Interest | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 5 | 3 |
Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 |
Profit before tax | 8 | 14 | 16 | 16 | 16 | 26 | 27 | 34 | 44 |
Tax % | 33% | 33% | 38% | 36% | 34% | 24% | 24% | 25% | |
6 | 9 | 10 | 10 | 11 | 20 | 20 | 25 | 33 | |
EPS in Rs | 0.07 | 0.12 | 0.13 | 0.13 | 0.13 | 0.23 | 0.21 | 0.27 | 0.35 |
Dividend Payout % | 24% | 17% | 16% | 15% | 15% | 13% | -0% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | % |
3 Years: | % |
TTM: | 36% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | % |
3 Years: | % |
TTM: | 41% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 94% |
3 Years: | 29% |
1 Year: | 71% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 78 | 78 | 78 | 78 | 86 | 94 | 94 | 94 |
Reserves | 65 | 17 | 22 | 31 | 39 | 136 | 162 | 194 | 220 |
2 | 3 | 6 | 6 | 12 | 58 | 83 | 72 | 14 | |
33 | 42 | 31 | 61 | 50 | 28 | 39 | 44 | 45 | |
Total Liabilities | 123 | 140 | 138 | 175 | 180 | 308 | 378 | 405 | 372 |
50 | 50 | 46 | 46 | 55 | 94 | 91 | 120 | 117 | |
CWIP | -0 | -0 | -0 | 5 | 0 | 6 | 26 | -0 | 1 |
Investments | 7 | 9 | 6 | 23 | 36 | 43 | 64 | 66 | 86 |
66 | 80 | 85 | 101 | 89 | 165 | 197 | 219 | 168 | |
Total Assets | 123 | 140 | 138 | 175 | 180 | 308 | 378 | 405 | 372 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|
6 | 7 | 0 | 24 | 14 | 16 | 11 | -6 | |
-0 | -4 | 1 | -23 | -18 | -27 | -45 | 83 | |
-6 | -1 | 1 | -2 | 5 | 8 | 35 | -15 | |
Net Cash Flow | -1 | 2 | 2 | -1 | 1 | -2 | 1 | 62 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 92 | 71 | 66 | 91 | 91 | 114 | 124 | 144 |
Inventory Days | 29 | 36 | 34 | 43 | 29 | 51 | 55 | 49 |
Days Payable | 91 | 105 | 63 | 130 | 92 | 36 | 53 | 56 |
Cash Conversion Cycle | 29 | 1 | 37 | 4 | 27 | 129 | 126 | 137 |
Working Capital Days | 101 | 83 | 97 | 51 | 66 | 131 | 133 | 152 |
ROCE % | 15% | 16% | 15% | 13% | 10% | 11% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
19 Dec - Issuance of duplicate share certificates for shareholders.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 26 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Nov - Newspaper Publication of Financials for half year end at 30.09.2024
- Regulation 33(3) Of SEBI (LODR) Regulations, 2015 - Submission Of Standalone & Consolidated Unaudited Financial Results Along With Limited Review Report, Statement Of Assets And Liabilities And Cash Flow For The Quarter And Half Year Ended On 30Th September, 2024. 11 Nov
-
Board Meeting Intimation for Corporate Announcement U/R 29(1)(A) Of SEBI (LODR) Regulations, 2015 Regarding Intimation Of Holding Board Meeting For Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results,
4 Nov - Board meeting to approve Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview
The company manufactures and markets 500+ pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. It is also involved in trading commodities and rental of properties. [1]